Dianthus Therapeutics (NASDAQ:DNTH) Now Covered by TD Cowen

Research analysts at TD Cowen assumed coverage on shares of Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) in a note issued to investors on Friday, Marketbeat Ratings reports. The brokerage set a "buy" rating on the stock.

DNTH has been the subject of several other research reports. Raymond James raised shares of Dianthus Therapeutics to a "moderate buy" rating in a report on Thursday, December 12th. HC Wainwright reaffirmed a "buy" rating and set a $40.00 price target on shares of Dianthus Therapeutics in a research report on Monday, November 11th. Finally, Oppenheimer lifted their price objective on Dianthus Therapeutics from $48.00 to $52.00 and gave the company an "outperform" rating in a report on Monday, November 11th. Eight equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat, Dianthus Therapeutics has an average rating of "Buy" and an average target price of $46.43.

Dianthus Therapeutics Stock Performance

NASDAQ:DNTH traded up $0.76 during mid-day trading on Friday, hitting $23.80. The company had a trading volume of 389,926 shares, compared to its average volume of 205,798. Dianthus Therapeutics has a fifty-two week low of $7.75 and a fifty-two week high of $33.77. The firm has a market cap of $704.41 million, a P/E ratio of -9.52 and a beta of 1.74. The business's fifty day moving average is $25.77 and its two-hundred day moving average is $26.60.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last released its quarterly earnings data on Thursday, November 7th. The company reported ($0.74) earnings per share for the quarter, missing the consensus estimate of ($0.59) by ($0.15). Dianthus Therapeutics had a negative return on equity of 21.68% and a negative net margin of 1,250.32%. The firm had revenue of $2.17 million for the quarter, compared to the consensus estimate of $1.07 million. Equities analysts forecast that Dianthus Therapeutics will post -2.61 earnings per share for the current year.

Institutional Investors Weigh In On Dianthus Therapeutics

Institutional investors have recently bought and sold shares of the company. SG Americas Securities LLC bought a new stake in shares of Dianthus Therapeutics in the second quarter worth $112,000. Bank of New York Mellon Corp raised its holdings in Dianthus Therapeutics by 860.5% during the second quarter. Bank of New York Mellon Corp now owns 80,935 shares of the company's stock worth $2,095,000 after acquiring an additional 72,509 shares in the last quarter. Rhumbline Advisers acquired a new position in Dianthus Therapeutics during the second quarter valued at approximately $832,000. American Century Companies Inc. increased its position in shares of Dianthus Therapeutics by 38.6% during the 2nd quarter. American Century Companies Inc. now owns 30,432 shares of the company's stock worth $788,000 after purchasing an additional 8,473 shares during the last quarter. Finally, WINTON GROUP Ltd bought a new stake in shares of Dianthus Therapeutics during the 2nd quarter worth approximately $265,000. Institutional investors own 47.53% of the company's stock.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.